SpyGlass Pharma (SGP) reported Monday that four-year trial data for its implanted eye drug delivery system showed that average internal eye pressure dropped 37%, and that 86% of participants stopped using daily prescription eye drops.
The biopharmaceutical company said 90% of patients maintained 20/25 or better vision during the four-year period. It also said the trial recorded no drug- or device-related adverse events, and patient vision and eye structures remained stable.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments